These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 39058796

  • 1. Pamidronate Response in a Novel Biallelic CREB3L1 Gene Mutation-Associated Osteogenesis Imperfecta: A Case Report.
    Selina A, Kandagaddala M, Madhuri V.
    JBJS Case Connect; 2024 Jul 01; 14(3):. PubMed ID: 39058796
    [Abstract] [Full Text] [Related]

  • 2. Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with Pamidronate.
    Lindahl K, Kindmark A, Rubin CJ, Malmgren B, Grigelioniene G, Söderhäll S, Ljunggren Ö, Åström E.
    Bone; 2016 Jun 01; 87():11-8. PubMed ID: 26957348
    [Abstract] [Full Text] [Related]

  • 3. Effect of intravenous pamidronate treatment in children with osteogenesis imperfecta.
    Atta I, Iqbal F, Lone SW, Ibrahim M, Khan YN, Raza J.
    J Coll Physicians Surg Pak; 2014 Sep 01; 24(9):653-7. PubMed ID: 25233970
    [Abstract] [Full Text] [Related]

  • 4. Intravenous pamidronate in osteogenesis imperfecta type VII.
    Cheung MS, Glorieux FH, Rauch F.
    Calcif Tissue Int; 2009 Mar 01; 84(3):203-9. PubMed ID: 19137231
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Homozygosity for CREB3L1 premature stop codon in first case of recessive osteogenesis imperfecta associated with OASIS-deficiency to survive infancy.
    Lindahl K, Åström E, Dragomir A, Symoens S, Coucke P, Larsson S, Paschalis E, Roschger P, Gamsjaeger S, Klaushofer K, Fratzl-Zelman N, Kindmark A.
    Bone; 2018 Sep 01; 114():268-277. PubMed ID: 29936144
    [Abstract] [Full Text] [Related]

  • 8. Bisphosphonate therapy for osteogenesis imperfecta.
    Dwan K, Phillipi CA, Steiner RD, Basel D.
    Cochrane Database Syst Rev; 2014 Jul 23; (7):CD005088. PubMed ID: 25054949
    [Abstract] [Full Text] [Related]

  • 9. Cyclic intravenous pamidronate for an infant with osteogenesis imperfecta type II.
    Fukahori K, Nirei J, Yamawaki K, Nagasaki K.
    BMJ Case Rep; 2023 May 15; 16(5):. PubMed ID: 37188488
    [Abstract] [Full Text] [Related]

  • 10. Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate.
    Munns CF, Rauch F, Zeitlin L, Fassier F, Glorieux FH.
    J Bone Miner Res; 2004 Nov 15; 19(11):1779-86. PubMed ID: 15476577
    [Abstract] [Full Text] [Related]

  • 11. Long-Term Bisphosphonate Therapy in Osteogenesis Imperfecta.
    Biggin A, Munns CF.
    Curr Osteoporos Rep; 2017 Oct 15; 15(5):412-418. PubMed ID: 28823022
    [Abstract] [Full Text] [Related]

  • 12. Pamidronate in children and adolescents with osteogenesis imperfecta: effect of treatment discontinuation.
    Rauch F, Munns C, Land C, Glorieux FH.
    J Clin Endocrinol Metab; 2006 Apr 15; 91(4):1268-74. PubMed ID: 16434452
    [Abstract] [Full Text] [Related]

  • 13. Long-term follow-up in osteogenesis imperfecta type VI.
    Trejo P, Palomo T, Montpetit K, Fassier F, Sato A, Glorieux FH, Rauch F.
    Osteoporos Int; 2017 Oct 15; 28(10):2975-2983. PubMed ID: 28689307
    [Abstract] [Full Text] [Related]

  • 14. Therapy with pamidronate in children with osteogenesis imperfecta.
    Marginean O, Tamasanu RC, Mang N, Mozos I, Brad GF.
    Drug Des Devel Ther; 2017 Oct 15; 11():2507-2515. PubMed ID: 28894358
    [Abstract] [Full Text] [Related]

  • 15. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.
    Land C, Rauch F, Travers R, Glorieux FH.
    Bone; 2007 Mar 15; 40(3):638-44. PubMed ID: 17127117
    [Abstract] [Full Text] [Related]

  • 16. Pamidronate affects the mandibular cortex of children with osteogenesis imperfecta.
    Apolinário AC, Figueiredo PT, Guimarães AT, Acevedo AC, Castro LC, Paula AP, Paula LM, Melo NS, Leite AF.
    J Dent Res; 2015 Mar 15; 94(3 Suppl):95S-102S. PubMed ID: 25608973
    [Abstract] [Full Text] [Related]

  • 17. Responsiveness to pamidronate treatment is not related to the genotype of type I collagen in patients with osteogenesis imperfecta.
    Kanno J, Saito-Hakoda A, Kure S, Fujiwara I.
    J Bone Miner Metab; 2018 May 15; 36(3):344-351. PubMed ID: 28528406
    [Abstract] [Full Text] [Related]

  • 18. Cyclic pamidronate therapy in children with osteogenesis imperfecta: results of treatment and follow-up after discontinuation.
    Andiran N, Alikasifoglu A, Gonc N, Ozon A, Kandemir N, Yordam N.
    J Pediatr Endocrinol Metab; 2008 Jan 15; 21(1):63-72. PubMed ID: 18404974
    [Abstract] [Full Text] [Related]

  • 19. Treatment response to long term antiresorptive therapy in osteogenesis imperfecta type VI: does genotype matter?
    Celik NB, Gonc N, Ozon A, Alikasifoglu A, Rauch F, Kandemir N.
    J Pediatr Endocrinol Metab; 2020 Dec 16; 33(12):1617-1624. PubMed ID: 33031053
    [Abstract] [Full Text] [Related]

  • 20. Development of scoliosis in young children with osteogenesis imperfecta undergoing intravenous bisphosphonate therapy.
    Kashii M, Kanayama S, Kitaoka T, Makino T, Kaito T, Iwasaki M, Kubota T, Yamamoto T, Ozono K, Yoshikawa H.
    J Bone Miner Metab; 2019 May 16; 37(3):545-553. PubMed ID: 30187275
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.